ArticleBreast cancer (Dove Medical Press)2026
Radiological and Histopathological Predictors of Survival in Neuroendocrine Differentiated Breast Cancer: A Comparative Analysis with NS-IDC.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to compare the radiological and immunohistochemical (IHC) features of neuroendocrine differentiated breast cancer (NEBC) with those of non-specific invasive ductal carcinoma (NS-IDC) and to examine the prognostic relevance of these features, including their association with overall survival (OS). Patients and Methods: Patients with histopathologically confirmed NEBC between 2015 and 2022 were retrospectively identified. Inclusion criteria were availability of preoperative mammography, ultrasonography, and magnetic resonance imaging (MRI), along with complete clinical records; patients with missing data were excluded. A randomly selected NS-IDC cohort from the same institutional database served as the comparison group. Histopathology was the reference standard. Imaging was reassessed by two breast radiologists, and pathological specimens were reviewed by an experienced breast pathologist. Statistical analyses were performed using IBM SPSS 26.0, with significance set at p < 0.05. Results: Eighty-five patients (44 NEBC, 41 NS-IDC) were included. Compared with NS-IDC, NEBC more frequently demonstrated rapid initial enhancement and late washout on MRI (p=0.001 and p=0.009, respectively), and higher progesterone reseptor (PR) expression (p=0.037). Five-year OS did not differ significantly between groups (p = 0.858). Multivariate analysis revealed that the presence of ductal carcinoma in situ (DCIS), T stage, and T2 hyperintensity on MRI emerged as independent predictors of mortality (p = 0.006, p = 0.003, and p = 0.028, respectively). Conclusion: Although NEBC exhibits distinct MRI characteristics and a predominantly hormone-positive IHC profile, survival outcomes were comparable to those of NS-IDC. Notably, T2 hyperintensity on MRI was the strongest imaging feature associated with poorer survival, suggesting a potential role in future prognostic stratification. The modest sample size, prognostic interpretations should be viewed as exploratory. Larger prospective studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.